Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline landscape.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Factors contributing to cervical dysplasia include using immunosuppressants and smoking. Signs and symptoms include genital warts, abnormal bleeding, spotting after intercourse, vaginal discharge and low back pain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 3 molecules, respectively.Cervical Intraepithelial Neoplasia (CIN).

Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Intraepithelial Neoplasia (CIN) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cervical Intraepithelial Neoplasia (CIN) Overview 7
Therapeutics Development 8
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 8
Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis 9
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 10
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes 11
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 14
Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes 15
Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 16
CEL-SCI Corp 16
Genexine Inc 17
Inovio Pharmaceuticals Inc 18
PDS Biotechnology Corp 19
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 20
Transgene SA 21
Vaccibody AS 22
Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ABI-1968 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
aminolevulinic acid hydrochloride - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GLBL-101c - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GX-188E - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Leukocyte Interleukin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PDS-0101 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
TG-4001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
VB-1016 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
VGX-3100 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 60
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 61
Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 62
Featured News & Press Releases 62
Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 62
Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016 62
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress 63
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 63
Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe 65
Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe 65
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 66
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 67
Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 68
May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 69
Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 70
Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 71
Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 71
May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2016 8
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corp, H2 2016 16
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Genexine Inc, H2 2016 17
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 18
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corp, H2 2016 19
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 20
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Transgene SA, H2 2016 21
Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2016 60
Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2016 61